Baldur Hjaltason, who oversees EPAX's strategic business development, will be a featured speaker at Nutracon's "Brain Storm" panel on Thursday, March 11 from 2 to 3:30 p.m at the Hilton Anaheim in Anaheim, Calif. Hjaltason and the other members of the panel will discuss trends, science, marketability and credibility of ingredients in the cognitive health category.
"I look forward to participating in this Nutracon panel and sharing EPAX's perspective on the cognitive health area," said Hjaltason. "EPAX's marine-based omega-3 concentrates are condition-specific with different EPA/DHA ratios depending on the health focus. The EPAX 1050 TG omega-3 concentrate with a high level of DHA fatty acids has demonstrated an effect on age-related memory decline. The OmegAD Study at the Karolinska Institute in Sweden used these EPAX concentrates and was the first clinical intervention study on patients with Alzheimer's Dementia (AD) given a DHA preparation."